Novo Nordisk (NVO) shares are slimming down. Shares of the Wegovy maker tanked more than 5% on Monday as the company failed to impress Wall Street at its capital markets day. The company came up short by not sharing more specifics around near-term growth targets amid fierce competition in the weight loss drug market. The company said it's targeting more than $23 billion in pipeline sales by 2035. It has plans to launch more than five potential multi-blockbusters by the end of the decade. (NVO ) Go deeper with AlphaSpace 43.24 +0.05 (+0.12%) At close: September 18 at 4:04:12 PM EDT "We have a situation where competition, as we are seeing it, has never been at least in Novo's historical back.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。